CG Oncology (CGON) Cash & Equivalents (2023 - 2026)

CG Oncology (CGON) has 4 years of Cash & Equivalents data on file, last reported at $33.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 18.74% year-over-year to $33.7 million; the trailing twelve-month figure through Mar 2026 stood at $33.7 million (down 18.74% YoY), and the FY2025 full-year result was $32.5 million, down 87.36% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $33.7 million, up from $32.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $257.1 million in Q4 2024 and bottomed at $8.3 million in Q4 2023.
• The 4-year median for Cash & Equivalents is $37.6 million (2025), against an average of $57.9 million.
• The widest annual swing landed in 2024, when Cash & Equivalents surged 3009.94%; it then tumbled 87.36% in 2025.
• A 4-year view of Cash & Equivalents shows it stood at $8.3 million in 2023, then soared by 3009.94% to $257.1 million in 2024, then sank by 87.36% to $32.5 million in 2025, then increased by 3.72% to $33.7 million in 2026.
• The last three Cash & Equivalents figures came in at $33.7 million (Q1 2026), $32.5 million (Q4 2025), and $45.1 million (Q3 2025), per Business Quant data.

Peer Comparison